Viemed Healthcare 2025 Q1 Earnings Strong Performance as Net Income Surges 64%

Viemed Healthcare reported its fiscal 2025 Q1 earnings on May 07th, 2025. The company exceeded expectations with robust financial results, showcasing a 17% increase in net revenue and a 64% rise in net income compared to the same quarter last year. Viemed raised its guidance for 2025, anticipating net revenue between $256 million and $265 million, up from the previous range of $254 million to $265 million. Adjusted EBITDA is now projected to be between $55 million and $58 million, reflecting confidence in sustained growth.

Revenue
The total revenue of Viemed Healthcare increased by 16.9% to $59.13 million in 2025 Q1, up from $50.59 million in 2024 Q1.

Earnings/Net Income
Viemed Healthcare's EPS rose 75.0% to $0.07 in 2025 Q1 from $0.04 in 2024 Q1, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $2.71 million in 2025 Q1, marking 69.1% growth from $1.60 million in 2024 Q1. The Company has sustained profitability for 8 years over the corresponding fiscal quarter, reflecting stable business performance. The EPS performance indicates positive financial health and effective business strategies.

Price Action
The stock price of Viemed Healthcare has edged down 2.55% during the latest trading day, has edged up 2.83% during the most recent full trading week, and has climbed 5.67% month-to-date.

Post-Earnings Price Action Review
Over the past five years, Viemed Healthcare's strategy of purchasing shares post-revenue drop quarter-over-quarter and holding them for 30 days yielded a 29.4% return, underperforming the S&P 500's 47.4% return in the same period. While the 30-day holding period allowed for partial recovery, the overall performance remained lackluster due to weak outcomes following revenue declines. The strategy highlighted challenges in capturing market recovery, emphasizing the impact of revenue fluctuations on stock performance and investor returns.

CEO Commentary
Casey Hoyt, CEO of Viemed Healthcare, expressed satisfaction with the significant improvements across all business segments during the traditionally challenging first quarter. He noted that the enhanced performance stems from strategic investments in the sales organization and technology, enabling organic growth through an expanded sales team and new market entries. Hoyt emphasized the company’s strong balance sheet, which supports the modernization of their ventilator fleet and the upcoming acquisition of Lehan's Medical Equipment, positioning Viemed for continued growth. He maintained a positive outlook, highlighting that the business remains unaffected by broader market volatility and tariffs.

Guidance
Viemed Healthcare anticipates net revenue for the full year 2025 to range between $256 million and $265 million, an increase from the previous guidance of $254 million to $265 million. Adjusted EBITDA is now expected to be between $55 million and $58 million, up from the earlier range of $54 million to $58 million. The company has not included the impact from the acquisition of Lehan's Medical Equipment in this guidance, signaling a potential update once the acquisition is finalized in the third quarter.

Additional News
Viemed Healthcare recently announced its agreement to acquire Lehan's Medical Equipment, an Illinois-based healthcare company specializing in respiratory care and women's health, for approximately $26 million. This strategic acquisition is expected to close in the third quarter of 2025 and is anticipated to complement Viemed's growth in complex respiratory, sleep, and staffing services. The acquisition is funded through cash on hand and borrowings from existing credit facilities. Viemed's CEO Casey Hoyt expressed optimism about the acquisition's potential to enhance service offerings and contribute to long-term growth.